<SUBMISSION>
<ACCESSION-NUMBER>0001181431-08-017988
<TYPE>4
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20080307
<FILING-DATE>20080311
<DATE-OF-FILING-DATE-CHANGE>20080311
<ISSUER>
<COMPANY-DATA>
<CONFORMED-NAME>ACADIA PHARMACEUTICALS INC
<CIK>0001070494
<ASSIGNED-SIC>2834
<IRS-NUMBER>061376651
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<BUSINESS-ADDRESS>
<STREET1>3911 SORRENTO VALLEY BLVD
<CITY>SAN DIEGO
<STATE>CA
<ZIP>92121
<PHONE>858-558-2871
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>3911 SORRENTO VALLEY BLVD
<CITY>SAN DIEGO
<STATE>CA
<ZIP>92121
</MAIL-ADDRESS>
</ISSUER>
<REPORTING-OWNER>
<OWNER-DATA>
<CONFORMED-NAME>Aasen Thomas H
<CIK>0001291969
</OWNER-DATA>
<FILING-VALUES>
<FORM-TYPE>4
<ACT>34
<FILE-NUMBER>000-50768
<FILM-NUMBER>08682067
</FILING-VALUES>
<BUSINESS-ADDRESS>
<PHONE>(858) 558-2871
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>3911 SORRENTO VALLEY BOULEVARD
<CITY>SAN DIEGO
<STATE>CA
<ZIP>92121
</MAIL-ADDRESS>
</REPORTING-OWNER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>rrd199146.xml
<DESCRIPTION>FORM 4 -- ANNUAL GRANT 7MAR08
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0202</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2008-03-07</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001070494</issuerCik>
        <issuerName>ACADIA PHARMACEUTICALS INC</issuerName>
        <issuerTradingSymbol>ACAD</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001291969</rptOwnerCik>
            <rptOwnerName>Aasen Thomas H</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>3911 SORRENTO VALLEY BOULEVARD</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>SAN DIEGO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92121</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Vice Pres., CFO, Treas. &amp; Sec.</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>8.32</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2008-03-07</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>26000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2018-03-06</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>26000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>26000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">25% of the shares subject to the Stock Option vest and become exercisable on March 7, 2009. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Glenn F. Baity, attorney-in-fact</signatureName>
        <signatureDate>2008-03-11</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.
<SEQUENCE>2
<FILENAME>rrd177767_200848.htm
<DESCRIPTION>POWER OF ATTORNEY
<TEXT>
<HTML>
<HEAD>
<TITLE>
rrd177767_200848.html
</TITLE>
</HEAD>
<BODY>
<PRE>
POWER OF ATTORNEY


	Know all by these presents, that the undersigned hereby authorizes Uli Hacksell, Glenn F. Baity or Kirk V. Crawford to execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of ACADIA Pharmaceuticals Inc. (the "Company"), Forms 3, 4 and 5 and any Amendments thereto or other forms or applications related thereto, and cause such
form(s) to be filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company.  The undersigned hereby grants to such attorney-in-fact full power and authority to
do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or substitute or substitutes of such attorney-in-fact, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

	This Power of Attorney shall (a) remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact and (b) replace the Power of Attorney, from June 2004, which relates to the same subject matter.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 11th day of March 2008.



	/s/ Thomas H. Aasen
	Thomas H. Aasen



</PRE>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
